Advanced in Myoclonic Epilepsy Associated With Ragged Red Fibers

Grainne S. Gorman

The Medical School Framlington Place, 
Newcastle Upon Tyne, ENG, GB 
Advanced in Myoclonic Epilepsy Associated With Ragged Red Fibers
The Medical School Framlington Place, 
Newcastle Upon Tyne, ENG, GB 
OverviewLocationsClinical Research

Overview

Grainne Gorman practices in Newcastle Upon Tyne, United Kingdom. Ms. Gorman is rated as an Advanced expert by MediFind in the treatment of Myoclonic Epilepsy Associated With Ragged Red Fibers. Her top areas of expertise are MELAS Syndrome, Progressive External Ophthalmoplegia, Paramyotonia Congenita, and Myotonic Dystrophy Type 2.

Her clinical research consists of co-authoring 149 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of Myoclonic Epilepsy Associated With Ragged Red Fibers.

Gender
Female

Locations

The Medical School Framlington Place, Newcastle Upon Tyne, ENG, United Kingdom
Other Locations
1501 North Campbell Avenue, Tucson, AZ 85724

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Tideglusib Versus Placebo for the Treatment of Children and Adolescents With Congenital Myotonic Dystrophy (REACH CDM)
A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Tideglusib Versus Placebo for the Treatment of Children and Adolescents With Congenital Myotonic Dystrophy (REACH CDM)
Enrollment Status: Completed
Publish Date: October 08, 2025
Intervention Type: Drug
Study Drug: Tideglusib
Study Phase: Phase 2/Phase 3
An Open-label Study to Evaluate the Safety and Tolerability of 12 Weeks Treatment With Oral REN001 in Patients With Primary Mitochondrial Myopathy (PMM), With an Optional Extension of Treatment
An Open-label Study to Evaluate the Safety and Tolerability of 12 Weeks Treatment With Oral REN001 in Patients With Primary Mitochondrial Myopathy (PMM), With an Optional Extension of Treatment
Enrollment Status: Terminated
Publish Date: July 16, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 1 Less Clinical Trial

148 Total Publications

RePOWER: An International, Prospective, Non-Interventional Registry of Patients With Primary Mitochondrial Myopathy.
RePOWER: An International, Prospective, Non-Interventional Registry of Patients With Primary Mitochondrial Myopathy.
Journal: Clinical genetics
Published: April 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Gorman's expertise for a condition
ConditionClose
    View All 11 Advanced Conditions
    View All 34 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile